17:58 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

FDA places hold on upcoming Phase I for point-of-care CAR Ts

FDA placed a clinical hold on an upcoming Phase I trial sponsored by Ziopharm Oncology Inc. (NASDAQ:ZIOP), which would be the first for its third-generation, point-of-care CAR T cells that require two days for manufacturing....
23:50 , Jun 18, 2018 |  BC Extra  |  Clinical News

Hold for upcoming point-of-care CAR T trial sinks Ziopharm shares

FDA placed a clinical hold on an upcoming Phase I trial sponsored by Ziopharm Oncology Inc. (NASDAQ:ZIOP), which would be the first for its third-generation, point-of-care CAR T cells that require two days for manufacturing....
20:38 , May 17, 2018 |  BC Innovations  |  Emerging Company Profile

Beyond B cells

PureTech Health plc subsidiary Vor Biopharma Inc. plans to combine CAR T therapies with hematopoietic stem cells modified to go unrecognized by CAR Ts. The approach could increase the types of immune cells that can...
17:59 , May 11, 2018 |  BC Extra  |  Company News

Intrexon slips after earnings report

Synthetic biology company Intrexon Corp. (NYSE:XON) sank $3.66 (20%) to $14.98 on Friday after it reported 1Q18 EPS and revenues that missed consensus estimates. Intrexon reported a loss per share of $0.33 on revenues of $43.8...
13:40 , Apr 13, 2018 |  BC Week In Review  |  Company News

Novartis to acquire AveXis for $8.7B

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring gene therapy company AveXis Inc. (NASDAQ:AVXS) for $218 per share, or about $8.7 billion. The price represents an 88% premium to AveXis' close of $115.91 on April 6, before...
19:43 , Apr 9, 2018 |  BC Extra  |  Company News

Novartis to acquire AveXis for $8.7B

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring gene therapy company AveXis Inc. (NASDAQ:AVXS) for $218 per share, or about $8.7 billion. The price represents an 88% premium to AveXis' close of $115.91 on Friday, before the...
20:29 , Mar 23, 2018 |  BC Extra  |  Company News

Management tracks: Sienna, Origenis

Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) said CFO Richard Peterson will retire, effective at the end of April. He will be succeeded by John Smither, who was CFO at Novan Inc. (NASDAQ:NOVN). Sienna also hired Caroline Van...
22:10 , Mar 22, 2018 |  BC Innovations  |  Translation in Brief

Switching scleroderma

While existing treatment options for localized scleroderma target inflammation, Fibrocell Science Inc. (NASDAQ:FCSC) and partner Intrexon Corp. (NYSE:XON) plan to enter the clinic next half with FCX-013, a therapy that could reverse fibrosis in patients...
05:25 , Jan 19, 2018 |  BC Week In Review  |  Financial News

Intrexon raises $86M in follow-on

Synthetic biology company Intrexon Corp. (NYSE:XON) raised $86 million on through the sale of 6.9 million shares at $12.50 in a follow-on underwritten by JMP Securities, Stifel and Northland Capital Markets. The figure includes the...
23:27 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Fibrocell reports Phase I/II data for FCX-007 in epidermolysis bullosa

In September, Fibrocell Science Inc. (NASDAQ:FCSC) reported interim data from a Phase I/II trial in 3 patients with recessive dystrophic epidermolysis bullosa (EB) showing that a single intradermal injection of FCX-007 led to >75% wound...